Efficacy of vincristine-ivermectin combination therapy in the treatment of canine transmissible venereal tumour (CTVT)

Vollständiger Abstract

Worum geht es in dieser Arbeit?

PICO Question In dogs diagnosed with canine transmissible venereal tumour (CTVT), does treatment with vincristine combined with ivermectin, compared to treatment with vincristine alone, lead to improved clinical outcomes? Clinical bottom line Category of research Treatment. Number and type of study designs reviewed Two randomised controlled trials. Strength of evidence Weak. Outcomes reported The studies collectively indicate that the combination of vincristine and ivermectin may be an effective and well-tolerated treatment for CTVT, with potential advantages over vincristine alone. One study demonstrated a statistically significant reduction in the number of treatment sessions for tumour remission, although methodological limitations and the absence of long-term follow-up limit the evidence. The other study observed comparable treatment efficacy across groups and a trend toward improved tolerability, despite the presence of cytomorphologically resistant types in the combination group; however, these differences were not statistically significant. Conclusion Ivermectin, a synthetic avermectin, may augment the action of vincristine when used for the treatment of CTVT. This may reduce the duration of therapy, lessen side effects, minimise recurrence and in turn reduce the animal’s suffering. Overall, the evidence to support this is assessed as weak.